Agreed. The mere fact that the purpose of Marqibo is to get the patients enough time to get to transplant is a valid argument in a highly terminal patient population. The fact that 2 patients were able to successfully get to transplantation is a new milestone in this group. If the committee does not approve this, it will be a signifcant loss for the cancer community.